CXC chemokine ligand 10 DNA vaccination plus Complete Freund's Adjuvant reverses hyperglycemia in non-obese diabetic mice.

Yoichi Oikawa, Akira Shimada, Yoshifumi Yamada, Yoshiaki Okubo, Takeshi Katsuki, Toshikatsu Shigihara, Jun Ichi Miyazaki, Shosaku Narumi, Hiroshi Itoh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Complete Freund's Adjuvant (CFA) is known to arrest autoimmune diabetes development in non-obese diabetic (NOD) mice. However, CFA alone cannot induce effective remission in diabetic NOD mice. Previously, we reported that anti-CXC chemokine ligand 10 (CXCL10) antibody can promote beta-cell proliferation in NOD mice. In the present study, we aimed to examine whether anti-CXCL10 plus CFA treatment can effectively reverse autoimmune diabetes development. Systemic supply of anti-CXCL10 antibody by CXCL10 DNA vaccination in combination with CFA injection was performed in new-onset diabetic NOD mice. Remission rate of diabetes, histological characteristics of residual insulitis lesions, residual beta-cell mass, and regulatory T cell population in local pancreas were examined. A high frequency of diabetes reversal was observed after combination treatment with anti-CXCL10 plus CFA. In mice showing diabetes reversal, residual beta-cell mass was significantly increased, and some beta-cells were in a proliferative state. Although systemic cytokine profiles were unaffected, the frequency of "hybrid regulatory T cells", i.e. regulatory T cells expressing CXCR3, was significantly increased in local pancreatic lesions. This was possibly associated with the regulation of anti-islet autoimmunity. Anti-CXCL10 plus appropriate immune adjuvant therapy arrested, and reversed, type 1 diabetes development.

Original languageEnglish
Pages (from-to)209-224
Number of pages16
JournalThe review of diabetic studies : RDS
Volume7
Issue number3
Publication statusPublished - 2010 Sep
Externally publishedYes

Fingerprint

CXC Chemokines
Inbred NOD Mouse
Freund's Adjuvant
Hyperglycemia
Vaccination
Ligands
DNA
Regulatory T-Lymphocytes
Type 1 Diabetes Mellitus
Antibodies
Autoimmunity
Pancreas
Therapeutics
Cell Proliferation
Cytokines
Injections
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

CXC chemokine ligand 10 DNA vaccination plus Complete Freund's Adjuvant reverses hyperglycemia in non-obese diabetic mice. / Oikawa, Yoichi; Shimada, Akira; Yamada, Yoshifumi; Okubo, Yoshiaki; Katsuki, Takeshi; Shigihara, Toshikatsu; Miyazaki, Jun Ichi; Narumi, Shosaku; Itoh, Hiroshi.

In: The review of diabetic studies : RDS, Vol. 7, No. 3, 09.2010, p. 209-224.

Research output: Contribution to journalArticle

Oikawa, Y, Shimada, A, Yamada, Y, Okubo, Y, Katsuki, T, Shigihara, T, Miyazaki, JI, Narumi, S & Itoh, H 2010, 'CXC chemokine ligand 10 DNA vaccination plus Complete Freund's Adjuvant reverses hyperglycemia in non-obese diabetic mice.', The review of diabetic studies : RDS, vol. 7, no. 3, pp. 209-224.
Oikawa, Yoichi ; Shimada, Akira ; Yamada, Yoshifumi ; Okubo, Yoshiaki ; Katsuki, Takeshi ; Shigihara, Toshikatsu ; Miyazaki, Jun Ichi ; Narumi, Shosaku ; Itoh, Hiroshi. / CXC chemokine ligand 10 DNA vaccination plus Complete Freund's Adjuvant reverses hyperglycemia in non-obese diabetic mice. In: The review of diabetic studies : RDS. 2010 ; Vol. 7, No. 3. pp. 209-224.
@article{5b7b1517d66c4f34b027acbf9724ed22,
title = "CXC chemokine ligand 10 DNA vaccination plus Complete Freund's Adjuvant reverses hyperglycemia in non-obese diabetic mice.",
abstract = "Complete Freund's Adjuvant (CFA) is known to arrest autoimmune diabetes development in non-obese diabetic (NOD) mice. However, CFA alone cannot induce effective remission in diabetic NOD mice. Previously, we reported that anti-CXC chemokine ligand 10 (CXCL10) antibody can promote beta-cell proliferation in NOD mice. In the present study, we aimed to examine whether anti-CXCL10 plus CFA treatment can effectively reverse autoimmune diabetes development. Systemic supply of anti-CXCL10 antibody by CXCL10 DNA vaccination in combination with CFA injection was performed in new-onset diabetic NOD mice. Remission rate of diabetes, histological characteristics of residual insulitis lesions, residual beta-cell mass, and regulatory T cell population in local pancreas were examined. A high frequency of diabetes reversal was observed after combination treatment with anti-CXCL10 plus CFA. In mice showing diabetes reversal, residual beta-cell mass was significantly increased, and some beta-cells were in a proliferative state. Although systemic cytokine profiles were unaffected, the frequency of {"}hybrid regulatory T cells{"}, i.e. regulatory T cells expressing CXCR3, was significantly increased in local pancreatic lesions. This was possibly associated with the regulation of anti-islet autoimmunity. Anti-CXCL10 plus appropriate immune adjuvant therapy arrested, and reversed, type 1 diabetes development.",
author = "Yoichi Oikawa and Akira Shimada and Yoshifumi Yamada and Yoshiaki Okubo and Takeshi Katsuki and Toshikatsu Shigihara and Miyazaki, {Jun Ichi} and Shosaku Narumi and Hiroshi Itoh",
year = "2010",
month = "9",
language = "English",
volume = "7",
pages = "209--224",
journal = "The review of diabetic studies : RDS",
issn = "1613-6071",
publisher = "Society for Biomedical Diabetes Research",
number = "3",

}

TY - JOUR

T1 - CXC chemokine ligand 10 DNA vaccination plus Complete Freund's Adjuvant reverses hyperglycemia in non-obese diabetic mice.

AU - Oikawa, Yoichi

AU - Shimada, Akira

AU - Yamada, Yoshifumi

AU - Okubo, Yoshiaki

AU - Katsuki, Takeshi

AU - Shigihara, Toshikatsu

AU - Miyazaki, Jun Ichi

AU - Narumi, Shosaku

AU - Itoh, Hiroshi

PY - 2010/9

Y1 - 2010/9

N2 - Complete Freund's Adjuvant (CFA) is known to arrest autoimmune diabetes development in non-obese diabetic (NOD) mice. However, CFA alone cannot induce effective remission in diabetic NOD mice. Previously, we reported that anti-CXC chemokine ligand 10 (CXCL10) antibody can promote beta-cell proliferation in NOD mice. In the present study, we aimed to examine whether anti-CXCL10 plus CFA treatment can effectively reverse autoimmune diabetes development. Systemic supply of anti-CXCL10 antibody by CXCL10 DNA vaccination in combination with CFA injection was performed in new-onset diabetic NOD mice. Remission rate of diabetes, histological characteristics of residual insulitis lesions, residual beta-cell mass, and regulatory T cell population in local pancreas were examined. A high frequency of diabetes reversal was observed after combination treatment with anti-CXCL10 plus CFA. In mice showing diabetes reversal, residual beta-cell mass was significantly increased, and some beta-cells were in a proliferative state. Although systemic cytokine profiles were unaffected, the frequency of "hybrid regulatory T cells", i.e. regulatory T cells expressing CXCR3, was significantly increased in local pancreatic lesions. This was possibly associated with the regulation of anti-islet autoimmunity. Anti-CXCL10 plus appropriate immune adjuvant therapy arrested, and reversed, type 1 diabetes development.

AB - Complete Freund's Adjuvant (CFA) is known to arrest autoimmune diabetes development in non-obese diabetic (NOD) mice. However, CFA alone cannot induce effective remission in diabetic NOD mice. Previously, we reported that anti-CXC chemokine ligand 10 (CXCL10) antibody can promote beta-cell proliferation in NOD mice. In the present study, we aimed to examine whether anti-CXCL10 plus CFA treatment can effectively reverse autoimmune diabetes development. Systemic supply of anti-CXCL10 antibody by CXCL10 DNA vaccination in combination with CFA injection was performed in new-onset diabetic NOD mice. Remission rate of diabetes, histological characteristics of residual insulitis lesions, residual beta-cell mass, and regulatory T cell population in local pancreas were examined. A high frequency of diabetes reversal was observed after combination treatment with anti-CXCL10 plus CFA. In mice showing diabetes reversal, residual beta-cell mass was significantly increased, and some beta-cells were in a proliferative state. Although systemic cytokine profiles were unaffected, the frequency of "hybrid regulatory T cells", i.e. regulatory T cells expressing CXCR3, was significantly increased in local pancreatic lesions. This was possibly associated with the regulation of anti-islet autoimmunity. Anti-CXCL10 plus appropriate immune adjuvant therapy arrested, and reversed, type 1 diabetes development.

UR - http://www.scopus.com/inward/record.url?scp=79960130342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960130342&partnerID=8YFLogxK

M3 - Article

C2 - 21409313

AN - SCOPUS:79960130342

VL - 7

SP - 209

EP - 224

JO - The review of diabetic studies : RDS

JF - The review of diabetic studies : RDS

SN - 1613-6071

IS - 3

ER -